David Lebovitz

Stock Analyst at Citigroup

(4.06)
# 646
Out of 4,496 analysts
40
Total ratings
66.1%
Success rate
7.19%
Average return

13 Stocks

Alnylam Pharmaceuticals
Jun 25, 2024
Maintains: Buy
Price Target: $227$291
Current: $237.83
Upside: +22.36%
Mirum Pharmaceuticals
May 9, 2024
Maintains: Buy
Price Target: $37$38
Current: $39.49
Upside: -3.77%
Madrigal Pharmaceuticals
May 8, 2024
Maintains: Buy
Price Target: $389$382
Current: $287.24
Upside: +32.99%
BioMarin Pharmaceutical
Apr 25, 2024
Maintains: Neutral
Price Target: $94$91
Current: $84.09
Upside: +8.22%
Crinetics Pharmaceuticals
Mar 6, 2024
Initiates: Buy
Price Target: $68
Current: $52.66
Upside: +29.13%
PTC Therapeutics
Oct 27, 2023
Downgrades: Sell
Price Target: $29$17
Current: $32.63
Upside: -47.90%
Blueprint Medicines
Feb 1, 2022
Maintains: Equal-Weight
Price Target: $111$92
Current: $114.97
Upside: -19.98%
Ionis Pharmaceuticals
Mar 23, 2021
Maintains: Underweight
Price Target: n/a
Current: $47.82
Upside: -
Rhythm Pharmaceuticals
Mar 2, 2021
Maintains: Overweight
Price Target: n/a
Current: $49.57
Upside: -
MacroGenics
Feb 26, 2021
Maintains: Underweight
Price Target: n/a
Current: $4.92
Upside: -
Ironwood Pharmaceuticals
Feb 22, 2021
Maintains: Equal-Weight
Price Target: n/a
Current: $6.72
Upside: -
Karyopharm Therapeutics
Jul 2, 2020
Initiates: Overweight
Price Target: n/a
Current: $0.89
Upside: -
Ascendis Pharma
Apr 2, 2020
Maintains: Overweight
Price Target: n/a
Current: $135.21
Upside: -